Clinical Trial Update: Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) [Phase 2]

View source ↗

Summary

The BrightStar-2 Phase 2 trial evaluating brigatinib in combination with chemotherapy or local consolidation therapy for ALK-positive advanced non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN